Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-A02617-48 | Other Identifier | ID RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Groupe Éthique et Santé | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
In obese patients, the prevalence of obstructive sleep apnea (OSA) is around 40% in men and 30% in women. Weight loss after bariatric surgery significantly improves OSA, with 75% of patients having a reduction in OSA severity or becoming non-apneic. We hypothesize a similar effect on OSA of nutritional and psychocomportemental rehabilitation for obese patients. However, we expect weight loss and blood pressure reduction to probably be lower in obese patients who have OSA and nutritional rehabilitation alone than in those who are treated for their OSA or are without OSA. To address this question, we will conduct an observational study on obese patients, treated or not for OSA, following nutritional and psychocomportemental rehabilitation.
In obese patients, OSA prevalence is around 40% in men and 30% in women. Being overweight or obese are independent risk factors for OSA, and the prevalence increases with body mass index (BMI). Weight loss after bariatric surgery is one treatment for OSA, 75% of patients having a reduction in OSA severity or becoming non-apneic. OSA and obesity both induce type 2 diabetes, hypertension and/or nonalcoholic fatty liver disease (NAFLD). A randomized study (Chirinos et al. NEJM 2014) demonstrated a better improvement in blood pressure, triglyceride levels or insulin resistance with weight loss alone or weight loss associated with continuous positive airway pressure (CPAP) than with CPAP alone. We hypothesize a similar effect of nutritional and psychocomportemental rehabilitation on OSA. However, weight loss and blood pressure improvements could be lesser in untreated OSA patients than in treated OSA or non-OSA patients. It has been demonstrated that bariatric surgery reduces medication use such as antihypertensive or antidiabetic drugs, and thus a secondary objective is to determine whether nutritional and psychocomportemental rehabilitation similarly reduces medication use by the overweight and obese.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients already treated for OSA | The first group involves patients already diagnosed and treated for sleep apnea that will follow the nutritional psychocomportemental rehabilitation |
| |
| Patients with a high OSA risk | This group concerns patients with a high OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation |
| |
| Patients with a low OSA risk | This group concerns patients with a low OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nutritional psychocomportemental rehabilitation | Dietary Supplement | Nutritional psychocomportemental rehabilitation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in OSA risk before and after nutritional and psychocomportemental rehabilitation | Berlin questionnaire score of patients will be compared before and after weight loss (if any) by nutritional psychocomportemental reeducation | 25 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Difference in daytime sleepiness before and after nutritional and psychocomportemental rehabilitation | Epworth sleepiness score of patients will be compared before and after weight loss by nutritional psychocomportemental rehabilitation | 25 weeks |
| Weight loss according to OSA status |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Subjects covered by articles L1121-5 to L1121-8 of French law
Not provided
Not provided
Not provided
Not provided
Overweight and obese patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean-Louis PEPIN, MD, PhD | Grenoble Alpes University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chu Grenoble Alpes | Grenoble | 38043 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36498465 | Result | Bailly S, Fabre O, Cals-Maurette M, Pantagis L, Terrail R, Legrand R, Astrup A, Pepin JL. Impact of a Weight-Loss Rehabilitation Program on Sleep Apnea Risk and Subjective Sleepiness in Patients with Overweight/Obesity: The DietSleep Study. J Clin Med. 2022 Nov 22;11(23):6890. doi: 10.3390/jcm11236890. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D020181 | Sleep Apnea, Obstructive |
| D012891 | Sleep Apnea Syndromes |
| D006973 | Hypertension |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Weight loss will be compared according to the somnolence and/or OSA risk defined by Berlin score |
| 25 weeks |
| Change in Blood pressure according to OSA status | Blood pressure reduction between the beginning and the end of the dietary program will be compared according to OSA risk defined by Berlin score | 25 weeks |
| Change in Medication use according to OSA status | Change in the number of antihypertensive, antidiabetic and lipid lowering drug use will be compared according to the change in Berlin questionnaire score | 25 weeks |
| To assess the effect of Weight loss on OSA | To determine the percentage of patients stopping CPAP treatment after weight loss | 25 weeks |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D004700 | Endocrine System Diseases |